The first prescription medicine derived from cannabis, developed by GW Pharmaceuticals
GW Pharmaceuticals will continue to provide financial support to help prescribers identify those patients with multiple sclerosis (MS) being treated who will derive most benefit from treatment with Sativex.*
Sativex was developed and is manufactured by GW Pharmaceuticals in the UK
GW Pharmaceuticals has over 20 years of heritage and expertise in the research and development of cannabis-based medicines
Sativex is an oromucosal spray derived from extracts of Cannabis sativa L. (Cannabis leaf and flower), cultivated for controlled proportions of the active compounds delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).1
What is Sativex?
Sativex is a complex botanical mixture derived from the Cannabis sativa plant. It is an endocannabinoid system modulator containing delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD), as well as additional plant-derived cannabinoid and non-cannabinoid components.
Who is Sativex for?
Sativex is a licensed medication indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.1
Treatment with Sativex must be initiated and supervised by a physician with specialist expertise in treating this patient population.1
Sativex is contraindicated in the following groups of patients:1
- With hypersensitivity to cannabinoids or to any of the excipients
- With any known or suspected history or family history of schizophrenia, or other psychotic illness; history of severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition
- Who are breast feeding (in view of the considerable likely levels of cannabinoids in maternal breast milk and the potential adverse developmental effects in infants)
NB. Sativex should not be used during pregnancy unless the potential risks to the foetus and/or embryo are considered to be outweighed by the benefit of treatment. Men and women of child-bearing age should take reliable contraceptive precautions for the duration of the treatment and for three months after discontinuation of therapy.1 Patients on hormonal contraceptives should be advised to use an additional alternative, non-hormonal/reliable barrier method of birth control during Sativex therapy.1
UK Pay-For-Responders Scheme
This website has been developed to provide you with easy access to downloadable order forms for your convenience, should you wish to participate in the scheme. Please ensure that you have referred to the terms and conditions of the offer.
Identifying Sativex responders
A thorough evaluation of the severity of spasticity related symptoms, and of the response to standard anti-spasticity medication, should be performed before treatment with Sativex is started.
Sativex responders are defined as patients experiencing at least a 20% improvement in spasticity related symptoms on a 0-10 patient reported numeric scale after 4 weeks of treatment. If a clinically significant improvement in spasticity is not seen during this period, treatment should be stopped.1
Terms and conditions of the UK Pay-for-Responders scheme.